Pomerantz Law Firm Urges Investors in Aquestive Therapeutics to Join Class Action Lawsuit Following Major Stock Drop

Investor Alert: Class Action Lawsuit Against Aquestive Therapeutics

The legal landscape surrounding Aquestive Therapeutics, Inc. (NASDAQ: AQST) has intensified, with Pomerantz LLP announcing a class action lawsuit directed at the company. This comes following a significant downturn in the stock price amidst troubling news regarding their product, Anaphylm. Investors who have suffered losses are advised to act within the designated timeframe to participate in this legal action.

Key Details of the Class Action

On January 9, 2026, the FDA issued a letter to Aquestive highlighting deficiencies that halted discussions about labeling for their Anaphylm sublingual film product. This was a notable setback for the company, which had previously submitted a New Drug Application (NDA) for Anaphylm. The FDA’s notification not only affirmed an ongoing review but effectively postponed potential approval indefinitely. In the wake of this announcement, the company's stock experienced a sharp decline, dropping $2.30 (or 37.04%) to close at $3.91 per share.

With such a drastic market response, it’s evident that shareholders may feel aggrieved, leading to the initiation of the class action. This lawsuit claims that certain officers and directors at Aquestive may have engaged in securities fraud or unlawful business practices, which contributed to the investors' losses.

How to Join the Class Action

For those who acquired Aquestive securities during the Class Period, taking prompt action is crucial. Interested investors must submit their request to be appointed as Lead Plaintiff to the Court before May 4, 2026. Individuals can contact Danielle Peyton at Pomerantz through her email or phone number. Including essential details such as mailing address, phone number, and the number of shares purchased will facilitate the process.

As part of the firm’s long-standing commitment to fight for victims of securities fraud, Pomerantz aims to recover compensation for investors who were misled. This firm has made its mark in the legal industry, championing shareholder rights and successfully recovering substantial damages for its clients over its more than 85 years of operation.

Background on Pomerantz LLP

Based in New York with offices around the globe, Pomerantz LLP is well-respected for its expertise in corporate and antitrust class litigation. Founded by Abraham L. Pomerantz, who is known for his role in pioneering securities class actions, the firm continues to uphold his legacy by representing clients in financial disputes and malpractice cases.

The firm emphasizes that past results do not guarantee future outcomes, but their strong record showcases their effectiveness in advocating for the rights of investors. For more information about the class action or to access details of the complaint, interested parties can visit the firm’s website.

This lawsuit is a reminder of the volatility of the stock market and the legal protections available to investors who may find themselves victims of corporate misconduct. The actions taken by Pomerantz LLP signify a critical era in advocating for shareholders' rights, especially in light of the challenges faced by companies like Aquestive.

Conclusion

Investors holding stakes in Aquestive Therapeutics during the defined period should act quickly to ascertain their role in this class action. With impending deadlines, there’s an opportunity for aggrieved investors to potentially recover losses through collective legal action. Whether you are a seasoned investor or new to trading, being informed and proactive can make a significant difference in your investment journey.